← Human Trials & Peer-Reviewed Studies
The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV
Plain-language guide to PMID 31237318 (2019): placebo-controlled randomized controlled trial study of Tesamorelin and GHRH (Growth Hormone-Releasing Hormone).
Key Facts
- PMID
- 31237318
- Journal
- The Journal of frailty & aging
- Year
- 2019
- Study type
- Randomized Controlled Trial
- Authors
- Adrian S et al. (12 authors)
- DOI
- 10.14283/jfa.2018.45
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Tesamorelin and GHRH (Growth Hormone-Releasing Hormone), published as a randomized controlled trial.
The goals of this exploratory secondary analysis were to determine the effects of tesamorelin on muscle quality (density) and quantity (area).
Who Took Part
PubMed indexes the participants as adults, both men and women.
Computed tomography scans (at L4-L5) were used to quantify total and lean density (Hounsfield Units, HU) and area (centimeters2) of four trunk muscle groups using a semi-automatic segmentation image analysis program.
Differences between muscle area and density before and after 26 weeks of tesamorelin or placebo treatment were compared and linear regression models were adjusted for baseline and treatment arm.
How the Study Was Run
The design is described as randomized and placebo-controlled.
The participants were allocated by chance, so the Tesamorelin group and the comparison group should start out alike.
Some participants received a placebo instead of Tesamorelin, giving a reference point.
A time span of 26 weeks appears in the methods.
Secondary, exploratory analysis of two previously completed randomized (2:1), clinical trials.
People living with HIV and with abdominal obesity.
What Was Measured
PubMed files the paper under topics including Canada, Growth Hormone-Releasing Hormone, HIV Infections and Muscle, Skeletal.
The authors tagged it with the keywords IGF-1, Muscle quality, frailty, sarcopenia and visceral adipose tissue.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of Tesamorelin and GHRH (Growth Hormone-Releasing Hormone) over 26 weeks.
Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2019 (The Journal of frailty & aging), a journal based in United States.
More context: the Tesamorelin compound page and the GHRH (Growth Hormone-Releasing Hormone) compound page, all human trials.
Our Notes on the Compounds
Tesamorelin: GH pulse → liver IGF-1 → mTOR and PI3K-AKT (muscle).
GHRH (Growth Hormone-Releasing Hormone): The 44-amino-acid hypothalamic hormone that tells the pituitary to release growth hormone; sermorelin and tesamorelin are analogs.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.